A New Anti-Viral Drug Shows Potential to Protect Humans from Ebola Virus

Healthcare workers who were at the risk of contracting Ebola due to needlestick injuries were given favipiravir, an antiviral drug did not develop the disease.

Anti-viral based therapies promise to be a potential method to protect humans from the deadly Ebola virus, says a new study.

In the study, eight British health-care workers were evacuated to the Royal Free Hospital in London, UK after possible accidental exposure to Ebola virus in Sierra Leone between January and March 2015.

Needle-Free Inhalable Ebola Vaccine Useful in Remote Areas Devoid of Medical Personnel
A non-injectable vaccine showed positive results when tested on monkeys. It's easy to administer and also helps avoid the problem of needle disposal.

Four of the healthcare workers were considered to have been at significant risk of exposure to Ebola from needlestick injuries and were given post-exposure prophylaxis (PEP) with the antiviral drug favipiravir, with or without monoclonal antibodies. None of the health-care workers went on to develop Ebola. All eight healthcare workers remained healthy throughout the 42 day follow-up, with no signs of disease or detectable levels of virus in their blood.

Lead author Michael Jacobs of the Royal Free NHS Foundation Trust said that it was possible that none of these health-care workers were infected with Ebola virus, and added that they cannot know for sure whether or not post-exposure prophylaxis prevented the onset of Ebola-virus disease. However, Jacobs mentioned that two of the workers had needlestick injuries contaminated with fresh blood from patients with Ebola virus disease putting them at very high risk of transmission.

Jacobs concluded that a similar approach to treat household contacts of Ebola cases might work to prevent a major route of spread during an epidemic. The study was published in the Journal Lancet Infectious Diseases.

Clinical Trials for Two Ebola Vaccines Show No Adverse Reactions in Monkeys
There are other vaccines against Ebola that are already in human trials but they have reported side effects including fever and muscle and joint pain.

Source-ANI

Phase 1 Clinical Trial of Ebola Vaccine Passes Safety Test, Shows Good Immune Response
A new study has revealed that an experimental Ebola vaccine called VSV-EBOV appears safe and generates immune response in a small phase 1 clinical trial.

New Ebola Vaccine Proves to be Safe in an Early Trial
No serious adverse events were noted and antibodies were significantly increased in participants after administration of a new Ebola vaccine. This showed the drug has some potential.